Skip to main content
. 2011 Feb 24;6(2):e16408. doi: 10.1371/journal.pone.0016408

Figure 3. Plasma miR-92a value (miR-92a/miR-638) in patients with non-Hodgkin's lymphoma at various stages.

Figure 3

(A) Plasma miR-92a value (miR-92a/miR-638) in patients with diffuse large B-cell lymphoma at the time of diagnosis, in the relapse phase, and in the complete remission (CR) state. Decreased plasma miR-92a values recovered in the CR phase (P<.0001) but were still significantly lower than in normal subjects (P<.0001). Plasma miR-92a levels at relapse decreased again and the levels were similar to those at diagnosis. (B) Plasma miR-92a value (miR-92a/638) in patients with follicular lymphoma at the time of diagnosis (Dx), in the relapse phase, and in the CR or complete remission unconfirmed (CRu) states. Patients with CRu status had significantly lower plasma miR-92a/miR-638 values compared with those who had CR (P = .0186 by the Mann-Whitney test). (C) Plasma miR-92a values (miR-92a/miR-638) in patients with T-cell non-Hodgkin's lymphoma at the time of diagnosis, relapse phase, and complete remission (CR and CRu).